公开(公告)号：US20240316079A1

公开(公告)日：2024-09-26

申请号：US18261137

申请日：2021-02-26

Applicant: OBI PHARMA, INC.

Inventor： Jianxin Duan ,  Fanying Meng ,  Tianyang Qi ,  Chun-Chung Wang ,  Lu-Tzu Chen ,  Wan-Fen Li ,  Ming-Tain Lai

IPC: A61K31/675 ,  A61K31/404 ,  A61K31/513 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7068 ,  A61P35/00

CPC classification number: A61K31/675 ,  A61K31/404 ,  A61K31/513 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7068 ,  A61P35/00

Abstract: Provided are the use of the compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-ethyl-N,N′-bis(ethylene)phosphoramidate, or a pharmaceutically acceptable salt, isotopic variant or solvate thereof in the manufacture of a medicament for treating cancer, and a composition which comprises the above compound and at least one anti-cancer drug.

公开(公告)号：US20240216401A1

公开(公告)日：2024-07-04

申请号：US18288215

申请日：2021-04-28

Applicant: OBI Pharma, Inc.

Inventor： Ming-Tain LAI ,  Wan-Fen LI ,  Chun-Chung Wang ,  Lu-Tzu Chen

IPC: A61K31/675 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K31/675 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827

Abstract: A pharmaceutical composition, including a compound 1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-mtrophenyl)-1-N ethyl-N,N′-bis(ethylene)phosphoramidate and at least one therapeutic agent including a chemotherapeutic agent or biological agent, and its medical use are provided.

公开(公告)号：US20240084040A1

公开(公告)日：2024-03-14

申请号：US18264563

申请日：2022-02-09

Applicant: OBI PHARMA, INC.

Inventor： Jiann-Shiun LAI ,  Hui-Wen CHANG ,  Yin-Chieh KUO ,  Chi-Sheng HSIA ,  Woan Eng CHAN ,  Ming-Tain LAI

IPC: C07K16/46 ,  A61P35/00

CPC classification number: C07K16/468 ,  A61P35/00 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565

Abstract: The present invention provides antibody or the antigen-binding portion thereof bind to carbohydrate antigen, such as Globo series antigens (e.g. Globo H, SSEA-4 or SSEA-3). Also disclosed herein are pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

公开(公告)号：US11535585B2

公开(公告)日：2022-12-27

申请号：US17036588

申请日：2020-09-29

Applicant: OBI PHARMA, INC.

Inventor： Jian-Xin Duan ,  Yeyu Cao ,  Xiaohong Cai ,  Hailong Jiao ,  Jing Yuan Ma ,  Mark Matteucci

IPC: C07C217/58 ,  C07D405/12 ,  C07F9/6558 ,  A61K47/64 ,  C07D403/06 ,  A61K47/55 ,  A61P35/00 ,  C07D239/94 ,  C07D487/04 ,  C07D471/04 ,  C07C213/02 ,  C07D491/22 ,  C07H19/06 ,  A61K47/54

Abstract: Provided herein are compounds of formula I: wherein the variables are defined herein, processes of making them, and methods of treating cancer comprising administering such compounds.

公开(公告)号：US20220257730A1

公开(公告)日：2022-08-18

申请号：US17623072

申请日：2020-03-31

Applicant: OBI PHARMA, INC.

Inventor： Tzu-Wen Tsau ,  Yung-Kai Wang ,  Kuan-Cheng Shen ,  Yueh-Chin Wu ,  Cheng-Der Tony Yu ,  Yu-Chun Tseng

IPC: A61K38/48 ,  A61K47/42 ,  A61K47/18 ,  A61K47/02 ,  A61K47/26 ,  A61K47/12 ,  A61K9/19 ,  A61K47/64

Abstract: The present invention relates to a botulinum toxin type A complex, and a formulation thereof and a usage method therefor. The present invention provides the botulinum toxin type A complex, comprising an HA70 component, and an HA17 component, an HA33 component, an NTNH component, and a BoNT/A1 component, wherein the botulinum toxin complex has a molecular weight of 740-790 kDa. Compared with the existing botulinum toxin complexes, the botulinum toxin complex of the present invention is smaller in molecular weight and higher in safety, and has a comparable treatment effect.

公开(公告)号：US20210284719A1

公开(公告)日：2021-09-16

申请号：US16321417

申请日：2017-07-31

Applicant: OBI PHARMA, INC.

Inventor： Cheng-Der Tony YU ,  Woan Eng CHAN ,  Shu-Yu LEE ,  Jiann-Shiun LAI ,  I-Ju CHEN

IPC: C07K16/18 ,  G01N33/574 ,  A61K47/68 ,  A61K49/16 ,  A61K45/06

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

公开(公告)号：US20210228732A1

公开(公告)日：2021-07-29

申请号：US17160282

申请日：2021-01-27

Applicant: OBI Pharma, Inc.

Inventor： Cheng-Der Tony YU ,  Jiann-Shiun LAI ,  I-Ju CHEN ,  Chiu-Chun LIN

IPC: A61K47/68 ,  C07K16/28 ,  A61P35/00 ,  A61K31/4025 ,  A61K39/395 ,  C07K16/18 ,  C07K16/30

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnositcs. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.

公开(公告)号：US10815307B2

公开(公告)日：2020-10-27

申请号：US15824733

申请日：2017-11-28

Applicant: OBI PHARMA, INC.

Inventor： Cheng-Der Tony Yu ,  Jiann-Shiun Lai ,  I-Ju Chen ,  Cheng-Chi Wang ,  Yi-Chien Tsai

IPC: C07K16/30 ,  G01N33/574 ,  C12N5/16 ,  C07K16/44 ,  A61K39/00

Abstract: The present invention provides antibodies or the antigen-binding portion thereof, that bind to one or more carbohydrate antigens. Also disclosed herein are pharmaceutical pharmaceutical compositions and methods for the inhibition of cancer cells in a subject in need thereof. The pharmaceutical compositions comprise an antibody or an antigen-binding portion thereof and at least one pharmaceutically acceptable carrier.

公开(公告)号：US10409869B2

公开(公告)日：2019-09-10

申请号：US15752854

申请日：2016-11-15

Applicant: OBI Pharma, Inc.

Inventor： Jian-Xin Duan ,  Yeyu Cao ,  Xiaohong Cai ,  Hailong Jiao ,  Jing Yuan Ma ,  Mark Matteucci

IPC: C07D203/22 ,  A61K31/396 ,  G06F16/951 ,  G06F16/954 ,  G01N29/02 ,  G01N29/22 ,  G06F3/0484 ,  G06F17/22 ,  H03H9/02 ,  H03H9/10 ,  H03H9/25 ,  A61P35/00 ,  C07F9/564

Abstract: Provided herein are optically active compounds of the formulae (ii); and (III) and pharmaceutical compositions thereof. Also provided herein are processes of making these compounds and resolving the racemic mixture or the enrichment of same with in one of its enantiomers to provide (R)- and (S)-1-(3-(3-N,N-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-N,N′-bis(ethylene)phosphoramidate, and methods of treating cancer comprising administering such compounds.

公开(公告)号：US20180028629A1

公开(公告)日：2018-02-01

申请号：US15662162

申请日：2017-07-27

Applicant: OBI PHARMA, INC.

Inventor： Cheng-Der Tony YU ,  Peiwen YU ,  Kuo-Pao LAI ,  Wei-Han LEE ,  I-Ju CHEN ,  Shu-Yi LIN ,  Yih-Huang HSIEH

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55577 ,  A61K2039/6037 ,  A61K2039/6081 ,  A61K2039/627 ,  A61K2039/64

Abstract: The present disclosure encompasses immunogenic/therapeutic compositions including Globo series antigens (SSEA-4, Globo H or SSEA-3) glycoconjugates and therapeutic adjuvants (OBI-821 or OBI-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular, the therapeutic conjugates include a SSEA-4, Globo H or SSEA-3 moiety and a KLH moiety subunit linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines (single valent, bi-valent or tri-valent vaccines) for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. Exemplary immune response can be characterized by reduction of the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality.